Serving patients by transforming biotechnology
Our mission is to serve patients. That is why we research and develop innovate treatments with a focus on serious diseases that cannot (yet) be treated or cannot be treated sufficiently. Our therapeutic areas include oncology and hematology, cardiovascular diseases, bone health, neurosciences, inflammation and nephrology.
Robust and differentiated, our pipeline uses cutting-edge science and technology to develop medicines for serious diseases. Amgen focuses on high-quality candidates demonstrating significant and clinically relevant results. We use human genetic validation wherever possible to increase our chances of success.
– 33 pre-clinical and clinical targets with high-performance genetic support.
– The largest toolkit in the industry with 13 modalities.
– A mix of innovative molecules, new potential indications and biosimilars.
Find out more on www.amgen.be
R.E. s.a. Amgen n.v. Telecomlaan 5-7, 1831 Diegem – BL-NPS-1120-00008 (v1.0) – creation date: November 2020